Part 312 - Investigational New Drug (IND) Application

Part 312 of Title 21 CFR sets the requirements for filing an Investigational New Drug (IND) application, which allows a sponsor to begin clinical trials of a new drug in the United States. It outlines the information needed on safety, manufacturing, and study protocols, the categories of INDs, and the FDA's responsibilities for review, approval, and ongoing oversight.